Next Steps for CAR T Cells in B-Cell Lymphomas
Victor A. Chow, MD, discusses the next steps for chimeric antigen receptor T-cell therapy in patients with B-cell lymphomas.
Victor A. Chow, MD, a senior hematology/oncology fellow at the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discussed the next steps for chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell lymphomas.
The use of CAR T cells has been exciting in the field. Chow says this excitement has led to a lot of research and money investigating its potential in various settings. While CAR T cells have been approved for treatment of individuals after 2 or more lines of therapy, studies are now looking at moving this to the upfront setting.
Prospective trials comparing CAR T cells to autologous stem cell transplant will help determine which treatment a relapsed patient should receive. Chow expects to have a better understanding from these data in the next year or so.
See more fromthis study
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
